Collectively, these previous findings, together with the weakened stemness and elimination of spare respiratory capacity by ALA, led us to ask whether ALA treatment can sensitize MTAP-deficient GBM cells to TMZ, a standard of care drug for GBMs. This evidence concerns the gene MTAP and glioblastoma.